Last reviewed · How we verify

Entecavir + Fuzheng Huayu Tablet

ShuGuang Hospital · FDA-approved active Small molecule

Entecavir + Fuzheng Huayu Tablet is a Nucleoside reverse transcriptase inhibitor (entecavir component); traditional Chinese medicine formulation (Fuzheng Huayu component) Small molecule drug developed by ShuGuang Hospital. It is currently FDA-approved for Chronic hepatitis B with evidence of viral replication and/or hepatic fibrosis.

Entecavir inhibits hepatitis B virus reverse transcriptase to suppress viral replication, while Fuzheng Huayu Tablet is a traditional Chinese medicine formulation intended to support liver function and reduce fibrosis.

Entecavir inhibits hepatitis B virus reverse transcriptase to suppress viral replication, while Fuzheng Huayu Tablet is a traditional Chinese medicine formulation intended to support liver function and reduce fibrosis. Used for Chronic hepatitis B with evidence of viral replication and/or hepatic fibrosis.

At a glance

Generic nameEntecavir + Fuzheng Huayu Tablet
SponsorShuGuang Hospital
Drug classNucleoside reverse transcriptase inhibitor (entecavir component); traditional Chinese medicine formulation (Fuzheng Huayu component)
TargetHBV polymerase/reverse transcriptase (entecavir); multiple targets including hepatic stellate cells and inflammatory pathways (Fuzheng Huayu)
ModalitySmall molecule
Therapeutic areaHepatology / Infectious Disease
PhaseFDA-approved

Mechanism of action

Entecavir is a nucleoside reverse transcriptase inhibitor that blocks HBV polymerase activity, reducing viral load in chronic hepatitis B patients. Fuzheng Huayu Tablet contains traditional Chinese herbs (including Salvia miltiorrhiza, Silybum marianum, and others) purported to enhance hepatic microcirculation, reduce inflammation, and inhibit hepatic stellate cell activation to slow or reverse liver fibrosis. The combination aims to provide both antiviral and hepatoprotective effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Entecavir + Fuzheng Huayu Tablet

What is Entecavir + Fuzheng Huayu Tablet?

Entecavir + Fuzheng Huayu Tablet is a Nucleoside reverse transcriptase inhibitor (entecavir component); traditional Chinese medicine formulation (Fuzheng Huayu component) drug developed by ShuGuang Hospital, indicated for Chronic hepatitis B with evidence of viral replication and/or hepatic fibrosis.

How does Entecavir + Fuzheng Huayu Tablet work?

Entecavir inhibits hepatitis B virus reverse transcriptase to suppress viral replication, while Fuzheng Huayu Tablet is a traditional Chinese medicine formulation intended to support liver function and reduce fibrosis.

What is Entecavir + Fuzheng Huayu Tablet used for?

Entecavir + Fuzheng Huayu Tablet is indicated for Chronic hepatitis B with evidence of viral replication and/or hepatic fibrosis.

Who makes Entecavir + Fuzheng Huayu Tablet?

Entecavir + Fuzheng Huayu Tablet is developed and marketed by ShuGuang Hospital (see full ShuGuang Hospital pipeline at /company/shuguang-hospital).

What drug class is Entecavir + Fuzheng Huayu Tablet in?

Entecavir + Fuzheng Huayu Tablet belongs to the Nucleoside reverse transcriptase inhibitor (entecavir component); traditional Chinese medicine formulation (Fuzheng Huayu component) class. See all Nucleoside reverse transcriptase inhibitor (entecavir component); traditional Chinese medicine formulation (Fuzheng Huayu component) drugs at /class/nucleoside-reverse-transcriptase-inhibitor-entecavir-component-traditional-chinese-medicine-formulation-fuzheng-huayu-component.

What development phase is Entecavir + Fuzheng Huayu Tablet in?

Entecavir + Fuzheng Huayu Tablet is FDA-approved (marketed).

What are the side effects of Entecavir + Fuzheng Huayu Tablet?

Common side effects of Entecavir + Fuzheng Huayu Tablet include Lactic acidosis, Hepatitis flare upon discontinuation, Headache, Fatigue, Gastrointestinal disturbance (from herbal component).

What does Entecavir + Fuzheng Huayu Tablet target?

Entecavir + Fuzheng Huayu Tablet targets HBV polymerase/reverse transcriptase (entecavir); multiple targets including hepatic stellate cells and inflammatory pathways (Fuzheng Huayu) and is a Nucleoside reverse transcriptase inhibitor (entecavir component); traditional Chinese medicine formulation (Fuzheng Huayu component).

Related